will not be considered. The *https://www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of August 24, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include Docket No. FDA–2026–N–4699 for ''Expedited Investigational New Drug Pilot Program; Request for Information.'' Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov.* Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ''confidential.'' Any information marked as ''confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.*

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

FOR FURTHER INFORMATION CONTACT: Benjamin Cook, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 2, Rm. 2114, Silver Spring, MD 20993–0002, 240–338–4685, *ExpeditedINDPilot@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: In the **Federal Register** of June 24, 2026 (91 FR 37996), FDA published a notice to open a public docket to solicit input and comments on a proposal to establish a pilot program, the Expedited IND pilot program, to shorten the time it takes from drug identification to FIH study, while protecting clinical trial participants. FDA is extending the comment period until August 24, 2026. The Agency is taking this action to allow interested persons additional time to submit comments.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–14672 Filed 7–20–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Recharter for the Advisory Commission on Childhood Vaccines

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice.

SUMMARY: In accordance with the Federal Advisory Committee Act (FACA), the Department of Health and Human Services is hereby giving notice that the Advisory Commission on Childhood Vaccines (ACCV) has been rechartered. The effective date of the renewed charter is July 21, 2026.

FOR FURTHER INFORMATION CONTACT: CAPT George Reed Grimes, Director, Division of Injury Compensation Programs, Health Systems Bureau, HRSA, 5600 Fishers Lane, 14W–18, Rockville, Maryland 20857; 800–338–2382; or *ACCV@hrsa.gov.*

SUPPLEMENTARY INFORMATION: The ACCV provides advice and recommendations to the Secretary of Health and Human Services on policy, program development, and other matters of significance related to implementation of the National Vaccine Injury Compensation Program and concerning other matters as described under section 2119(f) of the Public Health Service Act (42 U.S.C. 300aa–19(f)).

The renewed charter for ACCV was approved on July 16, 2026. The filing date is July 21, 2026. Recharter of the ACCV gives authorization for the commission to operate until July 21, 2028.

A copy of the ACCV charter is available on the ACCV website at *https://www.hrsa.gov/advisory-committees/vaccines/index.html.* A copy of the charter also can be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The

website address for the FACA database is *http://www.facadatabase.gov/.*

Maria G. Button,

Director, Executive Secretariat.

[FR Doc. 2026–14649 Filed 7–20–26; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Council on Parkinson's Research, Care, and Services (ACPRCS).

This is the second meeting of the ACPRCS, which was established by the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson's Act of 2024 (Pub. L. 118–66). The Advisory Council is charged with providing advice to the HHS Secretary on Parkinson's-related issues. The meeting will include presentations from non-profit organizations focused on Parkinson's and related disorders; plans for producing a federal inventory of Parkinson's programs; and the Council Subcommittees will report out on their progress.

The meeting is virtual and will be open to the public to view via HHS Live Streaming: *www.hhs.gov/live.* Individuals wishing to participate in need of special assistance or other reasonable accommodations should submit a request to the Contact Person listed on this notice at least seven (7) business days prior to the meeting.

Name of Committee: Advisory Council on Parkinson's Research, Care, and Services (ACPRCS).

Date: August 24, 2026.

Time: 10:00 a.m. to 4:00 p.m.

Agenda: Presentations from non-profit organizations focused on Parkinson's and related disorders; a discussion of the federal inventory of Parkinson's programs; and progress reports from the Council Subcommittees.

Address: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Meeting Format: Virtual Meeting.

Cost: The meeting is free and open to the public.

Deadlines: Public Comment Due *Date:* August 10th by 5:00 p.m. ET. For public comment instructions and guidelines, see below.

Contact Person: Jordan Gladman, Ph.D., Deputy Executive Officer, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, *nationalPDplan@nih.gov.*

Public Comments: The ACPRCS welcomes written and oral/virtual public comments and asks the public to review and adhere to its Public Comment Guidelines provided at *https://www.ninds.nih.gov/current-research/trans-agency-activities/national-plan-end-parkinsons.*

Submissions are accepted in writing via email addressed to *NationalPDplan@nih.gov.* Please include the phrase ''public comment'' in the subject line as well as the body of the message. A limited number of slots are available for individuals to provide a 2–3-minute oral summary or excerpt of their written comment to the Council during the meeting via videoconference. For those interested in that opportunity, please indicate ''Interested in providing oral/virtual comment'' in your written submission, along with your name, email, and professional/organizational affiliation so that Council support staff can contact you if a slot is available.

For any given meeting, comment slots will be assigned on a first-come, first-served basis, with priority given to individuals and organizations that have not previously provided comments. This will help ensure that as many individuals and organizations as possible have an opportunity to share comments. Commenters going over their allotted 3-minute slot may be asked to conclude immediately in order to allow other comments and the rest of the meeting to proceed on schedule.

Public comment submissions received by 5:00 p.m. ET on August 10th will be provided to the Council prior to the meeting for their consideration. The Council is not able to respond individually to comments. All public comments become part of the public record. Attachments of copyrighted publications are not permitted, but web links or citations for any copyrighted works cited may be provided.

*Technical issue*s: If you experience any technical problems with the webcast, please email *nationalPDplan@nih.gov.*

*Disability Accommodation*s: All ACPRCS Full Council Meetings provide Closed Captioning through *www.hhs.gov/live.* Individuals whose full participation in the meeting will require special accommodations (*e.g.,* sign language or interpreting services) must submit a request to the Contact Person listed on the notice at least seven (7) business days prior to the meeting. Such requests should include a detailed description of the accommodation needed and a way for the ACPRCS to contact the requester if more information is needed to fill the request.

Meeting schedule subject to change.

More Information: Information about the ACPRCS is available on: *https://www.ninds.nih.gov/current-research/trans-agency-activities/national-plan-end-parkinsons.*

Dated: July 17, 2026.

Rosalind M Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–14666 Filed 7–20–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Neurological Disorders and Stroke Council.

The meeting will be open to the public as indicated below. Individuals who plan to participate and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Neurological Disorders and Stroke Council.

Date: August 10, 2026.

Open: August 10, 12:00 p.m. to 12:15 p.m.

Agenda: To discuss upcoming Concept Clearance Initiatives and other business of the Council. The meeting will be available via NIH Videocast. *https://videocast.nih.gov/.*

Closed: August 10, 2026, 12:15–1:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6001 Executive Boulevard, Room 1131, Rockville, Maryland 20852 (Virtual Meeting)

Contact Person: Andrea Meredith, Ph.D., Director, Extramural Activities, National